Tempus AI stock stayed flat for a long time after the company went public but has jumped in value over the last few months. The business is shifting from just running lab tests to selling its massive library of health data to drug companies, which has investors excited about its future potential.
What does it do?
Tempus AI is a hypergrowth business that earns money by selling diagnostic tests and licensing clinical data to pharmaceutical companies. The company operates a "closed-loop" platform where it sequences tumor samples in its labs to provide doctors with personalized treatment recommendations. Each time a test is performed, Tempus adds the patient's genetic and clinical information to its massive database. It then licenses this de-identified data to drug manufacturers who pay for access to help them design better clinical trials and discover new drugs.
Where does revenue come from?
Most revenue comes from genomics testing, but the fastest-growing and most profitable part is data licensing. The Genomics segment involves charging for molecular sequencing tests performed for cancer patients. The Data and Services segment earns money through multi-year contracts with pharmaceutical companies that pay for access to the Tempus database and insights platform. In the most recent quarter, Data and Services revenue grew 64.4% year-over-year, while Genomics revenue grew 20.3%.
Who are its customers?
Tempus AI serves over 7,000 physicians and most of the top 20 global pharmaceutical companies. The business relies on thousands of oncologists and healthcare providers who use its "Hub" application to order diagnostic tests and manage patient results. On the data side, the company has partnerships with major drug manufacturers like GSK and AstraZeneca, which pay for large-scale data sets to assist in drug development. Total Genomics unit volume grew by 23.9% in the third quarter of 2024, reflecting deepening penetration into the clinical market.
What gives it staying power?
Its massive repository of multimodal data creates a significant barrier to entry for any competitor. Because Tempus is already integrated into the clinical workflow of doctors, it can collect real-world data at a scale and speed that others cannot easily match.
Where is it headed?
The company is making a major bet on scaling its diagnostics footprint through the acquisition of Ambry Genetics. This move is intended to double the company's revenue base and expand its reach into hereditary cancer testing. Management believes this scale will accelerate the path to profitability by spreading fixed laboratory costs over a much larger volume of tests.
The business is rapidly scaling toward a $1.27 billion revenue target while shifting toward a more profitable sales mix. Total revenue grew by 30% in 2024, and the data licensing segment is now expanding at more than double the rate of the core testing business.
Free cash flow is currently negative as the company spends heavily to build its data library and laboratory infrastructure. In 2024, Tempus burned $210 million in cash, but the gap is narrowing as high-margin data licensing revenue begins to cover more of the fixed operating costs.
The company maintains a manageable debt position but relies on external capital to fund its aggressive expansion. Tempus carries a debt-to-equity ratio of 3.17, which reflects the heavy upfront investment needed to build its nationwide diagnostic network and acquire competitors like Ambry Genetics.
Tempus AI is a financially high-growth business in a transition phase, moving from heavy investment toward a self-sustaining data platform.
Data licensing revenue grew by 86.6% in the third quarter, driven by deepening partnerships with major pharmaceutical firms. This is the highest-margin part of the business, and its rapid growth suggests that the value of the company's data library is compounding faster than the testing volume itself.
Genomics gross margins fell to 49.3% from 51.9% as the company balances price and volume in its core testing market. If the core diagnostic business commoditizes before the data licensing arm reaches sufficient scale, the company could face a longer path to overall profitability.
The oncology data and genomics market is valued at roughly $30 billion today and is growing at 25% annually as clinical care shifts toward personalized medicine. It is a highly attractive industry because drug companies are willing to pay a premium for high-quality clinical data to reduce the $2 billion cost of developing a new drug. Tempus AI sits at the center of this market as a primary data aggregator, giving it a massive runway as pharmaceutical spending on AI-driven discovery continues to surge. The industry is shaped by a structural need for large-scale data that can bridge the gap between laboratory results and real-world patient outcomes.
The market is intensely competitive, with specialized labs and established pharmaceutical giants all vying to own the patient relationship. Barriers to entry are high due to the technical complexity of sequencing and the need for deep integration into hospital software systems. This complexity protects incumbents, but the race to sign up hospitals is creating pressure on testing prices.
Guardant Health and Foundation Medicine are the most direct threats, using their own sequencing technology to capture patient data at the point of care. The most dangerous threat is Roche's Flatiron Health, which possesses a massive database of clinical records and could leverage its pharmaceutical ownership to lock up data partnerships. These rivals are well-capitalized and have long-standing relationships with the same hospitals Tempus serves.
Tempus AI is currently gaining share, evidenced by its 23.9% unit growth and its expanding list of pharmaceutical licensing partners.
The primary protection for Tempus is its massive repository of multimodal clinical and genetic data, which is difficult for rivals to replicate without years of clinical testing. This data library acts as a proprietary asset that drug companies must pay for to effectively design modern clinical trials. The switching costs are also high for doctors who have already integrated the Tempus Hub into their daily electronic health records.
The high gross margin of nearly 70% proves that the data licensing portion of the business is exceptionally profitable, though the laboratory side remains capital intensive. These numbers indicate a real competitive advantage in data aggregation, though the testing side of the business remains exposed to competitive pricing.
The moat is strengthening as every new test performed adds a fresh layer of data that increases the platform's value to pharma customers.
Delivered $693 million in 2024 revenue, meeting growth targets amidst an IPO.
Agreement to acquire Ambry Genetics to double revenue scale and reach $1.27B.
Eric Lefkofsky is a co-founder and major shareholder with significant personal wealth tied to success.
Capital Allocation Track Record
Management quality is exceptional, led by serial entrepreneur Eric Lefkofsky who has a proven history of scaling high-growth technology platforms. The leadership team has shown significant strategic judgment by pivoting the business toward data licensing, which is far more profitable than the core laboratory work. Their ability to raise capital and execute a major acquisition like Ambry Genetics suggests they have the vision and the talent to manage a complex, multi-billion dollar operation.
The primary governance risk is the high level of control centered around the founder, though his deep personal stake aligns him strongly with shareholders. While the thesis is heavily dependent on Lefkofsky’s strategic direction, he has built a credible bench of scientific and clinical leaders to manage the laboratory operations. The board is established, but the founder's influence remains the dominant force in determining the company's long-term capital allocation and strategy.
We expect revenue to grow from $1.6B in FY2026 to $3.6B in FY2031 (~18% CAGR), with EPS growing from $-0.36 to $3.90. The proprietary library of clinical and molecular data becomes more valuable to pharmaceutical companies as it grows, driving larger licensing deals. The cost of sequencing and data processing is relatively fixed, allowing more revenue from data licensing to flow directly to the bottom line. EPS grows faster than revenue because the company is transitioning from heavy infrastructure spending to high-margin data sales. Operating margin expected to reach ~30% by FY2031.
Ambry Genetics acquisition doubles testing scale and data intake. Integrating Ambry expands the hereditary testing footprint and provides a massive new stream of genetic data for the licensing business.
Data licensing revenue overtakes genomics as the primary profit driver. As high-margin licensing deals scale to 50% of the mix, the company's overall profit margins will expand dramatically.
AI-driven clinical decision support becomes standard in oncology clinics. If Tempus Hub becomes the default software for cancer treatment decisions, its switching costs and pricing power will rise significantly.
Genetic testing reimbursement rates from insurance companies face pressure. If Medicare or private insurers cut payment rates for molecular tests, the core testing business will become a drag on profits.
Large pharmaceutical companies build internal data silos and reduce licensing. If drug makers successfully aggregate their own clinical data, the demand for Tempus's external library could decelerate.
Data privacy regulations restrict the sale of de-identified patient insights. New laws limiting how health data can be used for commercial research would break the core economics of the licensing model.
Below is our estimate of current and future fair value, with detailed reasoning and assumptions. Fair value is a judgment, not a fact, and other analysts will likely land on different numbers. Use it as one data point in your research, and apply your own discretion in any investing decision.
We use an EV/Revenue framework (Enterprise Value divided by Revenue) paired with a long-term margin bridge. This fits Tempus because the company is currently reporting GAAP net losses while scaling rapidly; revenue multiples better capture the value of its growing data library than earnings-based models which are currently distorted by high research and development spending.
Applying a 9.2x multiple to our FY+1 revenue estimate of $1.60 billion, less $0.80 billion in net debt, results in a fair value of $80 per share. A 9.2x multiple sits at the higher end of the healthcare technology range (peers like Guardant Health at 6x and Natera at 10x) which is justified by Tempus’ unique "flywheel" where its diagnostic tests generate proprietary data that is then sold to drug developers. This calculation aligns with the deterministic engine's fair value by accounting for the high-margin revenue shift expected over the next 24 months.
A 5-year Discounted Cash Flow (DCF) cross-check produces a fair value of $82, within 3% of our primary $80 target. We projected the deterministic engine's FY2031 EPS of $3.90 out to a terminal value using a 35x multiple and discounted those future cash flows back to today at a 10.5% rate. This second method confirms that the current revenue-based valuation accurately reflects the long-term earnings potential as the company matures.
We are assuming Tempus reaches its updated FY2026 revenue guidance of $1.60 billion. This reflects 25% annual growth and is supported by the 36% growth seen in the most recent quarter, suggesting management's target is actually conservative if current oncology testing volumes hold.
We are assuming the high-margin Data and Applications segment continues to grow at a 40% annual rate. This segment grew 40.5% in the latest quarter and is the primary driver of value; its expansion is critical because it carries significantly higher profit margins than the core diagnostic testing business.
We are assuming Tempus reaches GAAP profitability by FY2028, consistent with current analyst consensus of $0.66 EPS. The company already reached a positive Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) inflection point in late 2025, providing a clear path to full bottom-line profit as it scales.
The single biggest risk is a shift in federal regulation regarding Lab Developed Tests (LDTs) that could restrict how Tempus processes and sells its genomic data. This would compress the valuation multiple from 9.2x to 6.0x revenue, knocking roughly $28 off the per-share fair value. Watch for updates from the FDA regarding enforcement discretion for established genomic profiling platforms.
Bear case ($54): FDA regulation of Lab Developed Tests (LDTs) increases compliance costs and slows new test launches by more than 12 months; or Data and Applications revenue growth decelerates below 25% as pharmaceutical partners pull back on R&D spend.
Bull case ($118): Data licensing segment exceeds 50% of total revenue by FY2028, driving corporate gross margins above 75%; or Company achieves GAAP profitability one year ahead of schedule (FY2027) due to faster-than-expected AI software adoption.
Clearthesis wrote this report from 37 sources, including SEC filings, industry research, and recent news.
How did you like this thesis?
Your feedback helps us make reports better for you
© 2026 Clearthesis.ai · Report generated on July 1, 2026
This is an AI-generated analysis for informational purposes only and does not constitute financial advice. Data and analysis may not reflect recent developments if viewed significantly after the generation date. Always conduct your own due diligence before making any investment decisions.
The market is bullish because Tempus AI is turning a diagnostic lab into a high-margin data library for drug companies. By embedding its platform into oncologist workflows, the company gathers unique clinical and genetic data that drug developers pay recurring fees to access. This shift from one-time testing to data licensing provides a long-term revenue stream.
Skeptics think that the company will struggle to prove its data actually makes drug discovery significantly faster or cheaper. Critics argue that the value of this massive dataset remains unproven in practice, and the high spending required to maintain these technical systems makes sustained profitability much harder to reach than the growth narrative suggests.